This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
ELAN or USPH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ELAN vs. USPH: Which Stock Is the Better Value Option?
Best Value Stocks to Buy for October 6th
by Zacks Equity Research
ELAN, DINO and EMBC made it to the Zacks Rank #1 (Strong Buy) value stocks list on October 6, 2025.
Elanco Animal Health (ELAN) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Elanco Animal Health (ELAN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Elanco Animal Health (ELAN) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Elanco Animal Health (ELAN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Elanco Animal Health Incorporated (ELAN) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Elanco Animal Health (ELAN) delivered earnings and revenue surprises of +30.00% and +4.67%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
U.S. Physical Therapy (USPH) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
U.S. Physical Therapy (USPH) delivered earnings and revenue surprises of +14.08% and +3.78%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Curious about Elanco Animal Health (ELAN) Q2 Performance? Explore Wall Street Estimates for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Elanco Animal Health (ELAN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.
Addus HomeCare (ADUS) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Addus HomeCare (ADUS) delivered earnings and revenue surprises of +2.76% and +0.40%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Can Phosphate Binders Drive DaVita Stock Before Q2 Earnings?
by Zacks Equity Research
DVA rides early momentum from phosphate binders ahead of second-quarter 2025 earnings, but PD supply issues may cloud growth.
ELAN vs. USPH: Which Stock Is the Better Value Option?
by Zacks Equity Research
ELAN vs. USPH: Which Stock Is the Better Value Option?